2023-12-012024-11-302024-11-30false13012083BIOROSARY UK MEDICAL INVESTMENT LIMITED2025-06-0686102falseiso4217:GBPxbrli:pure130120832023-12-01130120832024-11-30130120832023-12-012024-11-30130120832022-12-01130120832023-11-30130120832022-12-012023-11-3013012083bus:SmallEntities2023-12-012024-11-3013012083bus:AuditExempt-NoAccountantsReport2023-12-012024-11-3013012083bus:FullAccounts2023-12-012024-11-3013012083bus:PrivateLimitedCompanyLtd2023-12-012024-11-3013012083core:WithinOneYear2024-11-3013012083core:AfterOneYear2024-11-3013012083core:WithinOneYear2023-11-3013012083core:AfterOneYear2023-11-3013012083core:ShareCapital2024-11-3013012083core:SharePremium2024-11-3013012083core:RevaluationReserve2024-11-3013012083core:OtherReservesSubtotal2024-11-3013012083core:RetainedEarningsAccumulatedLosses2024-11-3013012083core:ShareCapital2023-11-3013012083core:SharePremium2023-11-3013012083core:RevaluationReserve2023-11-3013012083core:OtherReservesSubtotal2023-11-3013012083core:RetainedEarningsAccumulatedLosses2023-11-3013012083core:LandBuildings2024-11-3013012083core:PlantMachinery2024-11-3013012083core:Vehicles2024-11-3013012083core:FurnitureFittings2024-11-3013012083core:OfficeEquipment2024-11-3013012083core:NetGoodwill2024-11-3013012083core:IntangibleAssetsOtherThanGoodwill2024-11-3013012083core:ListedExchangeTraded2024-11-3013012083core:UnlistedNon-exchangeTraded2024-11-3013012083core:LandBuildings2023-11-3013012083core:PlantMachinery2023-11-3013012083core:Vehicles2023-11-3013012083core:FurnitureFittings2023-11-3013012083core:OfficeEquipment2023-11-3013012083core:NetGoodwill2023-11-3013012083core:IntangibleAssetsOtherThanGoodwill2023-11-3013012083core:ListedExchangeTraded2023-11-3013012083core:UnlistedNon-exchangeTraded2023-11-3013012083core:LandBuildings2023-12-012024-11-3013012083core:PlantMachinery2023-12-012024-11-3013012083core:Vehicles2023-12-012024-11-3013012083core:FurnitureFittings2023-12-012024-11-3013012083core:OfficeEquipment2023-12-012024-11-3013012083core:NetGoodwill2023-12-012024-11-3013012083core:IntangibleAssetsOtherThanGoodwill2023-12-012024-11-3013012083core:ListedExchangeTraded2023-12-012024-11-3013012083core:UnlistedNon-exchangeTraded2023-12-012024-11-3013012083core:MoreThanFiveYears2023-12-012024-11-3013012083core:Non-currentFinancialInstruments2024-11-3013012083core:Non-currentFinancialInstruments2023-11-3013012083dpl:CostSales2023-12-012024-11-3013012083dpl:DistributionCosts2023-12-012024-11-3013012083core:LandBuildings2023-12-012024-11-3013012083core:PlantMachinery2023-12-012024-11-3013012083core:Vehicles2023-12-012024-11-3013012083core:FurnitureFittings2023-12-012024-11-3013012083core:OfficeEquipment2023-12-012024-11-3013012083dpl:AdministrativeExpenses2023-12-012024-11-3013012083core:NetGoodwill2023-12-012024-11-3013012083core:IntangibleAssetsOtherThanGoodwill2023-12-012024-11-3013012083dpl:GroupUndertakings2023-12-012024-11-3013012083dpl:ParticipatingInterests2023-12-012024-11-3013012083dpl:GroupUndertakingscore:ListedExchangeTraded2023-12-012024-11-3013012083core:ListedExchangeTraded2023-12-012024-11-3013012083dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-12-012024-11-3013012083core:UnlistedNon-exchangeTraded2023-12-012024-11-3013012083dpl:CostSales2022-12-012023-11-3013012083dpl:DistributionCosts2022-12-012023-11-3013012083core:LandBuildings2022-12-012023-11-3013012083core:PlantMachinery2022-12-012023-11-3013012083core:Vehicles2022-12-012023-11-3013012083core:FurnitureFittings2022-12-012023-11-3013012083core:OfficeEquipment2022-12-012023-11-3013012083dpl:AdministrativeExpenses2022-12-012023-11-3013012083core:NetGoodwill2022-12-012023-11-3013012083core:IntangibleAssetsOtherThanGoodwill2022-12-012023-11-3013012083dpl:GroupUndertakings2022-12-012023-11-3013012083dpl:ParticipatingInterests2022-12-012023-11-3013012083dpl:GroupUndertakingscore:ListedExchangeTraded2022-12-012023-11-3013012083core:ListedExchangeTraded2022-12-012023-11-3013012083dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-12-012023-11-3013012083core:UnlistedNon-exchangeTraded2022-12-012023-11-3013012083core:NetGoodwill2024-11-3013012083core:IntangibleAssetsOtherThanGoodwill2024-11-3013012083core:LandBuildings2024-11-3013012083core:PlantMachinery2024-11-3013012083core:Vehicles2024-11-3013012083core:FurnitureFittings2024-11-3013012083core:OfficeEquipment2024-11-3013012083core:AfterOneYear2024-11-3013012083core:WithinOneYear2024-11-3013012083core:ListedExchangeTraded2024-11-3013012083core:UnlistedNon-exchangeTraded2024-11-3013012083core:ShareCapital2024-11-3013012083core:SharePremium2024-11-3013012083core:RevaluationReserve2024-11-3013012083core:OtherReservesSubtotal2024-11-3013012083core:RetainedEarningsAccumulatedLosses2024-11-3013012083core:NetGoodwill2023-11-3013012083core:IntangibleAssetsOtherThanGoodwill2023-11-3013012083core:LandBuildings2023-11-3013012083core:PlantMachinery2023-11-3013012083core:Vehicles2023-11-3013012083core:FurnitureFittings2023-11-3013012083core:OfficeEquipment2023-11-3013012083core:AfterOneYear2023-11-3013012083core:WithinOneYear2023-11-3013012083core:ListedExchangeTraded2023-11-3013012083core:UnlistedNon-exchangeTraded2023-11-3013012083core:ShareCapital2023-11-3013012083core:SharePremium2023-11-3013012083core:RevaluationReserve2023-11-3013012083core:OtherReservesSubtotal2023-11-3013012083core:RetainedEarningsAccumulatedLosses2023-11-3013012083core:NetGoodwill2022-12-0113012083core:IntangibleAssetsOtherThanGoodwill2022-12-0113012083core:LandBuildings2022-12-0113012083core:PlantMachinery2022-12-0113012083core:Vehicles2022-12-0113012083core:FurnitureFittings2022-12-0113012083core:OfficeEquipment2022-12-0113012083core:AfterOneYear2022-12-0113012083core:WithinOneYear2022-12-0113012083core:ListedExchangeTraded2022-12-0113012083core:UnlistedNon-exchangeTraded2022-12-0113012083core:ShareCapital2022-12-0113012083core:SharePremium2022-12-0113012083core:RevaluationReserve2022-12-0113012083core:OtherReservesSubtotal2022-12-0113012083core:RetainedEarningsAccumulatedLosses2022-12-0113012083core:AfterOneYear2023-12-012024-11-3013012083core:WithinOneYear2023-12-012024-11-3013012083core:Non-currentFinancialInstrumentscore:CostValuation2023-12-012024-11-3013012083core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-12-012024-11-3013012083core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-12-012024-11-3013012083core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-12-012024-11-3013012083core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-12-012024-11-3013012083core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-12-012024-11-3013012083core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-12-012024-11-3013012083core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-12-012024-11-3013012083core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-12-012024-11-3013012083core:Non-currentFinancialInstrumentscore:CostValuation2024-11-3013012083core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-11-3013012083core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-11-3013012083core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-11-3013012083core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-11-3013012083core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-11-3013012083core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-11-3013012083core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-11-3013012083core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-11-3013012083core:Non-currentFinancialInstrumentscore:CostValuation2023-11-3013012083core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-11-3013012083core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-11-3013012083core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-11-3013012083core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-11-3013012083core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-11-3013012083core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-11-3013012083core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-11-3013012083core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-11-3013012083bus:Director12023-12-012024-11-3013012083bus:Director22023-12-012024-11-3013012083core:FurnitureFittingsToolsEquipment2023-11-3013012083core:FurnitureFittingsToolsEquipment2024-11-3013012083core:FurnitureFittingsToolsEquipment2023-12-012024-11-30

BIOROSARY UK MEDICAL INVESTMENT LIMITED

Registered Number
13012083
(England and Wales)

Unaudited Financial Statements for the Year ended
30 November 2024

BIOROSARY UK MEDICAL INVESTMENT LIMITED
Company Information
for the year from 1 December 2023 to 30 November 2024

Directors

GAO, Zhangyan
ZHANG, Xiaohong

Registered Address

792 Wickham Road
Croydon
CR0 8EA

Registered Number

13012083 (England and Wales)
BIOROSARY UK MEDICAL INVESTMENT LIMITED
Balance Sheet as at
30 November 2024

Notes

2024

2023

£

£

£

£

Fixed assets
Tangible assets364128
64128
Current assets
Cash at bank and on hand14,29522,151
14,29522,151
Creditors amounts falling due within one year4(42,190)(42,190)
Net current assets (liabilities)(27,895)(20,039)
Total assets less current liabilities(27,831)(19,911)
Net assets(27,831)(19,911)
Capital and reserves
Called up share capital100100
Profit and loss account(27,931)(20,011)
Shareholders' funds(27,831)(19,911)
The financial statements were approved and authorised for issue by the Board of Directors on 6 June 2025, and are signed on its behalf by:
ZHANG, Xiaohong
Director
Registered Company No. 13012083
BIOROSARY UK MEDICAL INVESTMENT LIMITED
Notes to the Financial Statements
for the year ended 30 November 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 105, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Revenue from rendering of services
Revenue from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.
Tangible fixed assets and depreciation
All fixed assets are initially recorded at cost. Property, plant and equipment is used in the company's principal activity for the production and supply of goods or for administrative purposes and is stated in the balance sheet under the historic cost model. This model requires the assets to be stated at cost less amounts in respect of depreciation and less any accumulated impairment losses. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value (which is the expected amount that would currently be obtained from disposal of an asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life), over the useful economic life of the respective asset as follows:

Straight line (years)
Fixtures and fittings4
2.Average number of employees

20242023
Average number of employees during the year00
3.Tangible fixed assets

Fixtures & fittings

Total

££
Cost or valuation
At 01 December 23255255
At 30 November 24255255
Depreciation and impairment
At 01 December 23127127
Charge for year6464
At 30 November 24191191
Net book value
At 30 November 246464
At 30 November 23128128
4.Creditors: amounts due within one year

2024

2023

££
Other creditors41,29041,290
Accrued liabilities and deferred income900900
Total42,19042,190
Other Creditors is made of Director's loan.
5.Share capital
100 Ordinary shares of £1 each